Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

Kidney / RCC

Kidney cancer and renal cell carcinoma.

Must-know

  1. 1

    KEYNOTE-564: ctDNA after adjuvant pembrolizumab or placebo in clear-cell renal cell carcinoma

    Choueiri et al. Journal of Clinical Oncology, 2026 ASCO Annual Meeting abstract 4502. 2026.

    994 patients were randomized to adjuvant pembrolizumab or placebo. Baseline ctDNA was detected in 40 of 736 (5.4%) with a 16-plex assay and 60 of 736 (8.2%) with a 64-plex assay. ctDNA positivity was associated with shorter disease-free survival in both arms. Sensitivity for a disease-free survival event was 12% and 15% with pembrolizumab and 10% and 15% with placebo.

    AbstractDana-Farber video

  2. 2

    Longitudinal ctDNA testing in metastatic renal cell carcinoma

    Basu et al. JCO Precision Oncology. 2024.

    In 92 patients with metastatic renal cell carcinoma (490 plasma samples), serial ctDNA negativity or clearance on therapy had a progression-free survival hazard ratio of 3.2 versus becoming or staying ctDNA positive. In the surveillance group (n = 32), longitudinally positive ctDNA had a hazard ratio of 18 versus serial negativity.

    PMID 39693589DOI

  3. 3

    K-COMPASS: KIM-1 and ctDNA in oligometastatic clear-cell renal cell carcinoma

    Tang et al. European Urology. 2026.

    In NCT03575611, baseline KIM-1 (hazard ratio 1.91, 95% CI 1.03–3.55) and ctDNA MRD (hazard ratio 2.47, 95% CI 1.08–5.64) were each associated with systemic therapy-free survival. The K-COMPASS model, those two markers plus four clinical variables, had a C-index of 0.76.

    PMID 41765697DOI

  4. 4

    Preoperative ctDNA in nonmetastatic renal cell carcinoma

    Ben-David et al. JCO Precision Oncology. 2024.

    Preoperative ctDNA was detected in 61% of patients with nonmetastatic renal cell carcinoma and correlated with clinical features. Recurrence after surgery was not the reported endpoint.

    PMID 39348609DOI

A randomized trial that assigned adjuvant therapy according to a ctDNA result was not identified. KEYNOTE-564 randomized pembrolizumab versus placebo; its ctDNA analysis is a meeting abstract. The Basu study is longitudinal testing in metastatic disease. K-COMPASS is a prognostic model from a single-arm metastasis-directed therapy trial. The last study reports preoperative detection, not recurrence after surgery.

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

Presentations

Accruing studies for Kidney / RCC

Trials

Education

OtherTier 3PinnedMRD / ctDNAConference data

Signatera Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers

A Natera press release dated November 5, 2026, describes a real-world SITC analysis of 424 patients on first-line immunotherapy for stage IV melanoma, kidney cancer, MSI-H colorectal cancer, or NSCLC: people with two consecutive negative Signatera results had 36-month overall survival of 93.2% versus 77.9% in all others (HR 0.24, P=0.0003), and among those complete molecular responders overall survival was 93.5% if immunotherapy continued and 89.4% if it stopped (P=0.42). These figures are from the company press release; the official SITC/JITC abstract was not retrieved.

Natera, Inc. company press release